Andrii Buvailo, PhD

Nowadays, mobile devices are ubiquitous with an estimated number of smartphones and tablet PCs to exceed two billion globally.

The availability of internet connection in most public places, powerful processors, and user-friendly touch screen technologies make mobile devices useful not …

(Last updated: October 2025)

Since 1950, when Alan Turing introduced the concept of 'thinking machines', artificial intelligence has steadily advanced—from the rise of neural networks in the 1980s to the release of OpenAI’s GPT-3 in 2020, which paved the …

Lantern Pharma’s AI-driven drug discovery platform RADR® enables value creation across multiple dimensions of the oncology drug development process: from the expansion of therapeutic indications and the identification of drug combinations for use in precision oncology, as well as the …

Brain-computer interface (BCI) technologies are rapidly becoming the spotlight of the neurotech industry, with Neuralink at the forefront. Recently, Neuralink implanted its first brain chip in a human, marking a significant milestone in human-computer interaction. This implant allows users …

Singapore’s Nanyang Biologics (NYB), a company working at the intersection of biodiversity and artificial intelligence, is preparing to list on Nasdaq through a US$ 1.5 billion business combination with RF Acquisition Corp II, a U.S. special purpose acquisition company.

The …

Foundation models represent a relatively new paradigm in artificial intelligence (AI), revolutionizing how machine learning models are developed and deployed.

Foundation models are a class of large-scale machine learning models, typically based on deep learning architectures such as transformers, that are …

Lila Sciences has raised $235 million in Series A financing, a round that values the Cambridge-based startup at more than $1 billion less than a year after its launch. The company is using the money to pursue a sweeping …

In a rare move for the pharmaceutical industry, Eli Lilly and Company has launched TuneLab, a platform that gives external biotech companies access to its proprietary AI models for drug discovery. These models have been trained on decades of …

OpenAI and Retro Biosciences have released new findings from a joint effort in AI-driven protein engineering. Using GPT-4b micro, a biology-specialized variant of GPT-4o, the team designed two modified versions of Yamanaka factors, RetroSOX and RetroKLF, that showed over 50-fold …

In medicinal chemistry, the “make” stage of the design–make–test–analyze (DMTA) cycle is often where good ideas go to die. Synthetic bottlenecks, expensive building blocks, low-yield reactions, and complications during scale-up for manufacturing can turn promising drug candidates into abandoned projects.